Andrew Winokur, MD
Psychiatry · Farmington, CTNPI 1700883097
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,216 of the $1,391 with a category attached, or 87.4%. Johnson & Johnson accounts for 94.5% of it on its own, with 1 other manufacturer making up the rest.
Across 7 payments — averaging $198.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$77
Across 124 payments — averaging $3558.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$278K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$101K
- Biohaven Pharmaceuticals, Inc.$31K
- Boehringer Ingelheim$21K
- Boehringer Ingelheim Pharma GmbH & Co.kg$6K
- AbbVie$5K
What the payments were for
- Travel & lodging$1,21687%
- Food & beverage$987%
- Education$776%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $1,314 |
| AbbVie | 2 | $77 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,216
How this compares
$1,391 in reported general payments places this provider in the 80th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 33 | $42,459 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,269 |
| Alprazolam ErAlprazolam | 11 | $1,247 |
| Trazodone Hcl | 36 | $735 |
| Mirtazapine | 19 | $600 |
| Clonazepam | 49 | $594 |
| Pregabalin | 25 | $592 |
| Buspirone Hcl | 20 | $507 |
| Prazosin Hcl | 20 | $439 |
| Zolpidem Tartrate | 42 | $371 |
| Lorazepam | 29 | $363 |
| Alprazolam | 23 | $307 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 18 | $288 |
| Eszopiclone | 22 | $287 |
| Lamotrigine | 12 | $285 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Farmington
- David MatuskeyFarmington$120K
- Jayesh KamathFarmington$11K
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.